The investment from the pharmaceutical giant aims to accelerate Enable’s manufacturing build-out. It follows the company’s 2024 announcement of plans to expand its Ohio manufacturing plant. Other uses for funds include strengthening supply chain capabilities and driving commercial growth.
Cincinnati-based Enable develops the enFuse syringe transfer system for drug delivery. enFuse, an on-body delivery system, provides subcutaneous abdominal bolus administration of drug or biologic products in accordance with the drug product requirements. The mechanical, wearable device can deliver large volumes of small molecule and biologic medications subcutaneously. Patients can receive their needed treatment in a single injection under the skin, rather than the intravenous route.
Enable Injections designed enFuse to streamline and improve in-clinic or patient self-administration. enFuse features hands-free, hidden needle drug delivery. The system received FDA approval for the delivery of Empaveli in October 2023, then CE mark last year. The company also has partnerships with companies such as Roche and Serina Therapeutics.
According to a news release, the funding strengthen’s the company’s ability to meet growing demand for enFuse. Sanofi used enFuse as part of its IRAKLIA phase 3 study in newly diagnosed multiple myeloma (MM) and the IZALCO phase 2 study in relapsed or refractory MM. The company also led the company’s 2018 Series B funding round and inked an official partnership in 2019.
“This investment from one of our key partners shows support of the enFuse platform and our shared commitment to making large-volume subcutaneous injectable therapies more convenient for patients, including oncology,” said Michael D. Hooven, chair and CEO of Enable Injections. “Expanding our manufacturing capabilities is key to meeting the needs of our partners while bringing innovative treatment options to patients, worldwide.”
